Pfizer Inc announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizers investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
- Read more about Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/pfizer-granted-fda-fast-track-designation-for-ervogastat-clesacostat-combination-for-the-treatment-of-non-alcoholic-steatohepatitis
No comments:
Post a Comment